Patent US3226815A successfully refreshed from Google Patents.
Patent US4605559A successfully refreshed from Google Patents.
US4605559A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compound, FR-900447, production and use thereof
Assignee: Astellas Pharma Inc
•
Filing: 1984-08-31
•
Granted: 1986-08-12
•
Expires: 2004-08-31
Abstract
Abstract The invention relates to a new compound, FR-900447, and pharmaceutically acceptable salts thereof having antimicrobial and antitumor activity, to a pharmaceutically composition thereof, and to a process for production thereof by culturing Streptomyces rubropurpureus FERM BP-584 in nutrient medium under aerobic condition.
Inventors
- 👤 Yasuhiro Hori
- 👤 Motohiro Hino
- 👤 Hiroshi Terano
- 👤 Masashi Hashimoto
- 👤 Masanobu Kohsaka
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 15:55
CPC Classifications
C; C12; C12P; C12P1/00; C12P1/06; A; A61; A61P; A61P31/00; A61P31/04; A61P35/00; C12N; C12N1/00; C12N1/20; C12N1/205; C12R; C12R2001/00; C12R2001/01; C12R2001/465; H; H05; H05K; H05K1/00; H05K1/02; H05K1/0296; H05K1/0298
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
380 words
A compound, FR-900447, or pharmaceutically acceptable salt thereof having the following characteristics as its free form: (1) has an elementary analysis (%): C59.05; H6.72; N5.57 (2) has a molecular weight: 928 [SIMS: m/z 929 (M + +1)] (3) has a melting point: 85° C. (dec.) (4) has an optical rotation: [α] D 23 ° =+291.4° (C=0.675, H 2 O) (5) has a characteristic ultraviolet absorption spectrum: λ max .spsp.H 2 .spsp.O =276 nm (E 1cm 1% 390) 340 nm (sh) (E 1cm 1% =80) λ max .spsp.H 2 .spsp.O+HCl =272 nm (E 1cm 1% =400), 330 nm (sh) (E 1cm 1% =82) λ max .spsp.H 2 .spsp.O+NaOH =243 nm (E 1cm 1% 275), 278 nm (E 1cm 1% =350), 410 nm (E 1cm 1% =31) (6) has a characteristic infrared absorption spectrum: ν max KBr =3400, 2950, 1650, 1560, 1465, 1435, 1395 (sh), 1375, 1280, 1150, 1075, 1040 (sh), 960, 895, 855, 840cm -1 (7) has a characteristic nuclear magnetic resonance absorption spectrum: δppm (pyridine-d 5 ): 10.62 (1H, t, J=6Hz), 8.38 (1H, s), 8.14 (1H, s), 6.90 (1H, s), 6.895 (1H, d, J=5 Hz), 6.43 (1H, s), 5.79 (1H, m), 5.80 (1H, d, J=10 Hz), 5.37 (1H, d, J=5 Hz), 4.48 (1H, q., J=6 Hz), 4.15 (1H, m), 3.9 (2H, m), 3.85 (1H, s), 3.63 (1H, t, J=10Hz), 3.47 (1H, m), 3.34 (1H, m), 3.12 (1H, m), 3.08 (2H, m), 3.07 (3H, s), 2.9 (1H, m), 2.82 (2H, m), 2.76 (6H, s), 2.74 (1H, m), 2.50 (6H, s), 2.19 (3H, s), 1.71 (3H, d, J=6Hz), 1.63 (2H, m), 1.62 (3H, d, J=6Hz), 1.47 (3H, d, J=5.4 Hz), 1.20 (3H, s) (8) is soluble in water, and is sparingly soluble in acetone and methanol, and is insoluble in chloroform, n-hexane and diethyl ether (9) is positive in color reaction with each of potassium permanganate, iodine vapor and ceric sulfate and is negative in Ehrlich's reaction, reaction with Dragendorff reagent and Molish's reaction (10) has a characteristic 13 C-nuclear magnetic resonance absorption spectrum: δ(ppm) (pyridine-d 5 ): 14.2, 17.3, 17.5, 19.4, 22.9, 31.1, 32.2, 33.5, 35.4, 36.1, 36.8, 40.2, 52.1, 55.6, 58.4, 64.6, 64.8, 68.3, 68.5, 70.5, 70.8, 72.2, 76.6, 78.1, 98.5, 107.1, 108.5, 121.6, 124.6, 124.9, 127.6, 131.0, 131.9, 132.4, 133.7, 137.0, 138.8, 155.1, 156.4, 162.5, 166.4, 174.7, 179.8, 187.3.
Claim 2
Dependent Claim
380 words
A compound, FR-900447, or pharmaceutically acceptable salt thereof having the following characteristics as its free form: (1) has an elementary analysis (%): C59.05; H6.72; N5.57 (2) has a molecular weight: 928 [SIMS: m/z 929 (M + +1)] (3) has a melting point: 85° C. (dec.) (4) has an optical rotation: [α] D 23 ° =+291.4° (C=0.675, H 2 O) (5) has a characteristic ultraviolet absorption spectrum: λ max .spsp.H 2 .spsp.O =276 nm (E 1cm 1% 390) 340 nm (sh) (E 1cm 1% =80) λ max .spsp.H 2 .spsp.O+HCl =272 nm (E 1cm 1% =400), 330 nm (sh) (E 1cm 1% =82) λ max .spsp.H 2 .spsp.O+NaOH =243 nm (E 1cm 1% 275), 278 nm (E 1cm 1% =350), 410 nm (E 1cm 1% =31) (6) has a characteristic infrared absorption spectrum: ν max KBr =3400, 2950, 1650, 1560, 1465, 1435, 1395 (sh), 1375, 1280, 1150, 1075, 1040 (sh), 960, 895, 855, 840cm -1 (7) has a characteristic nuclear magnetic resonance absorption spectrum: δppm (pyridine-d 5 ): 10.62 (1H, t, J=6Hz), 8.38 (1H, s), 8.14 (1H, s), 6.90 (1H, s), 6.895 (1H, d, J=5 Hz), 6.43 (1H, s), 5.79 (1H, m), 5.80 (1H, d, J=10 Hz), 5.37 (1H, d, J=5 Hz), 4.48 (1H, q., J=6 Hz), 4.15 (1H, m), 3.9 (2H, m), 3.85 (1H, s), 3.63 (1H, t, J=10Hz), 3.47 (1H, m), 3.34 (1H, m), 3.12 (1H, m), 3.08 (2H, m), 3.07 (3H, s), 2.9 (1H, m), 2.82 (2H, m), 2.76 (6H, s), 2.74 (1H, m), 2.50 (6H, s), 2.19 (3H, s), 1.71 (3H, d, J=6Hz), 1.63 (2H, m), 1.62 (3H, d, J=6Hz), 1.47 (3H, d, J=5.4 Hz), 1.20 (3H, s) (8) is soluble in water, and is sparingly soluble in acetone and methanol, and is insoluble in chloroform, n-hexane and diethyl ether (9) is positive in color reaction with each of potassium permanganate, iodine vapor and ceric sulfate and is negative in Ehrlich's reaction, reaction with Dragendorff reagent and Molish's reaction (10) has a characteristic 13 C-nuclear magnetic resonance absorption spectrum: δ(ppm) (pyridine-d 5 ): 14.2, 17.3, 17.5, 19.4, 22.9, 31.1, 32.2, 33.5, 35.4, 36.1, 36.8, 40.2, 52.1, 55.6, 58.4, 64.6, 64.8, 68.3, 68.5, 70.5, 70.8, 72.2, 76.6, 78.1, 98.5, 107.1, 108.5, 121.6, 124.6, 124.9, 127.6, 131.0, 131.9, 132.4, 133.7, 137.0, 138.8, 155.1, 156.4, 162.5, 166.4, 174.7, 179.8, 187.3.
Claim 3
Dependent Claim
46 words
A process for the production of FR-900447 as defined in claim 1, which comprises culturing the microorganism Streptomyces rubropurpureus FERM BP-584 in an aqueous nutrient medium under aerobic condition until substantial antimicrobial activity is imparted to said medium, and recovering FR-900447 from the resultant cultured broth.
Claim 4
Dependent Claim
30 words
An antimicrobial pharmaceutical composition which comprises an antimicrobially effective amount of a compound, FR-900447 as defined in claim 1, or pharmaceutically acceptable salt thereof and a non-toxic, pharmaceutically acceptable carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-08-11 | 1990-02-10 | 1990-08-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-08-11 | 1994-02-10 | 1994-08-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-08-11 | 1998-02-10 | 1998-08-12 | $7700.00 | Window Closed / Lapsed |